Literature DB >> 16415174

MCP-1/CCR2-dependent loop for fibrogenesis in human peripheral CD14-positive monocytes.

Norihiko Sakai1, Takashi Wada, Kengo Furuichi, Kazuaki Shimizu, Satoshi Kokubo, Akinori Hara, Junya Yamahana, Toshiya Okumura, Kouji Matsushima, Hitoshi Yokoyama, Shuichi Kaneko.   

Abstract

Monocyte/macrophage (Momicron) migration to sites of inflammation is a prerequisite cause of organ fibrosis. The recruitment and activation of Mo are regulated by C-C chemokines, especially monocyte chemoattractant protein-1 [(MCP-1)/CC chemokine ligand 2], which interacts with CC chemokine receptor 2 (CCR2). However, the mechanisms leading to fibrosis via MCP-1/CCR2 signaling in Mo remain to be investigated. The effect of MCP-1 on the expression of MCP-1, CCR2, transforming growth factor-beta1 (TGF-beta1), and type I collagen in circulating human CD14-positive Mo was investigated. In addition, the impact of MCP-1-specific or TGF-beta1-specific antisense (AS) phosphorothioate oligodeoxynucleotides (ODN) was examined to explore the involvement of autocrine/paracrine production of MCP-1 and TGF-beta1 by human CD14-positive Mo. Furthermore, specific CCR2 inhibitors were applied to examine the involvement of CCR2 signaling for the promotion of a fibrogenic response. The stimulation of Mo with MCP-1 increased mRNA levels of TGF-beta1 and a pro-alpha1 chain of type I collagen (COL1A1) as well as protein synthesis. Similarly, the expression of MCP-1 and CCR2 was enhanced by the stimulation with MCP-1 in dose- and time-dependent manners. This positive loop via MCP-1 was reduced by pretreatment with MCP-1-specific AS-ODN. It was also noted that pretreatment with TGF-beta1-specific AS-ODN partially reduced COL1A1 mRNA levels. Finally, transcripts of these molecules were suppressed by pretreatment with specific CCR2 inhibitors. The present study demonstrated that human peripheral CD14-positive Mo contribute directly to fibrogenesis by a MCP-1/CCR2-dependent amplification loop. These data suggest that fibrogenic processes in Mo regulated by MCP-1/CCR2 may be novel, therapeutic targets for combating organ fibrosis.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16415174     DOI: 10.1189/jlb.0305127

Source DB:  PubMed          Journal:  J Leukoc Biol        ISSN: 0741-5400            Impact factor:   4.962


  33 in total

1.  Disruption of mammalian target of rapamycin complex 1 in macrophages decreases chemokine gene expression and atherosclerosis.

Authors:  Ding Ai; Hongfeng Jiang; Marit Westerterp; Andrew J Murphy; Mi Wang; Anjali Ganda; Sandra Abramowicz; Carrie Welch; Felicidad Almazan; Yi Zhu; Yury I Miller; Alan R Tall
Journal:  Circ Res       Date:  2014-03-31       Impact factor: 17.367

2.  Addition of angiotensin II type 1 receptor blocker to CCR2 antagonist markedly attenuates crescentic glomerulonephritis.

Authors:  Maki Urushihara; Naro Ohashi; Kayoko Miyata; Ryousuke Satou; Omar W Acres; Hiroyuki Kobori
Journal:  Hypertension       Date:  2011-01-31       Impact factor: 10.190

3.  MCP-1/CCR2B-dependent loop upregulates MUC5AC and MUC5B in human airway epithelium.

Authors:  Maria E Monzon; Rosanna Malbrán Forteza; S Marina Casalino-Matsuda
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2010-11-19       Impact factor: 5.464

4.  CD137-mediated pathogenesis from chronic hepatitis to hepatocellular carcinoma in hepatitis B virus-transgenic mice.

Authors:  Jun Wang; Wenxia Zhao; Liang Cheng; Mingzhou Guo; Dongling Li; Xiaozhu Li; Yi Tan; Suping Ma; Suyun Li; Yunsheng Yang; Lieping Chen; Shengdian Wang
Journal:  J Immunol       Date:  2010-11-08       Impact factor: 5.422

5.  Deficiency of chemokine receptor CCR1 causes osteopenia due to impaired functions of osteoclasts and osteoblasts.

Authors:  Akiyoshi Hoshino; Tadahiro Iimura; Satoshi Ueha; Sanshiro Hanada; Yutaka Maruoka; Mitsuori Mayahara; Keiko Suzuki; Toshio Imai; Masako Ito; Yoshinobu Manome; Masato Yasuhara; Takaaki Kirino; Akira Yamaguchi; Kouji Matsushima; Kenji Yamamoto
Journal:  J Biol Chem       Date:  2010-06-22       Impact factor: 5.157

6.  CCR2 promotes hepatic fibrosis in mice.

Authors:  Ekihiro Seki; Samuele de Minicis; Sayaka Inokuchi; Kojiro Taura; Katsumi Miyai; Nico van Rooijen; Robert F Schwabe; David A Brenner
Journal:  Hepatology       Date:  2009-07       Impact factor: 17.425

7.  Functional contribution of elevated circulating and hepatic non-classical CD14CD16 monocytes to inflammation and human liver fibrosis.

Authors:  Henning W Zimmermann; Sebastian Seidler; Jacob Nattermann; Nikolaus Gassler; Claus Hellerbrand; Alma Zernecke; Jens J W Tischendorf; Tom Luedde; Ralf Weiskirchen; Christian Trautwein; Frank Tacke
Journal:  PLoS One       Date:  2010-06-10       Impact factor: 3.240

8.  Selective CCR2-targeted macrophage depletion ameliorates experimental mesangioproliferative glomerulonephritis.

Authors:  L M McIntosh; J L Barnes; V L Barnes; J R McDonald
Journal:  Clin Exp Immunol       Date:  2008-11-25       Impact factor: 4.330

9.  Dual role of CCR2 in the constitution and the resolution of liver fibrosis in mice.

Authors:  Claudia Mitchell; Dominique Couton; Jean-Pierre Couty; Marie Anson; Anne-Marie Crain; Vinciane Bizet; Laurent Rénia; Stanislas Pol; Vincent Mallet; Hélène Gilgenkrantz
Journal:  Am J Pathol       Date:  2009-04-09       Impact factor: 4.307

10.  Nf1+/- monocytes/macrophages induce neointima formation via CCR2 activation.

Authors:  Waylan K Bessler; Grace Kim; Farlyn Z Hudson; Julie A Mund; Raghuveer Mali; Keshav Menon; Reuben Kapur; D Wade Clapp; David A Ingram; Brian K Stansfield
Journal:  Hum Mol Genet       Date:  2016-01-05       Impact factor: 6.150

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.